TrialHaematologica2023

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

Thomas Pabst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.